Effect of adjuvant budesonide therapy on clinical outcomes,inflammatory factors and disease regression in patients with hypereosinophilic AECOPD
Objective:To analyse the effects of adjuvant budesonide therapy on clinical outcomes,inflammatory factors,and disease regression in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)with high eosinophils.Methods:108 patients with hypereosinophilic AECOPD who underwent treatment in our hospital from January 2019 to December 2022 were selected as the study objects.The patients were divided into a control group(n=53)and an observation group(n=55)according to the different treatment method.The control group were treated with tiotropium bromide dry powder capsules,while the observation group were treated with budesonide suspension nebulised inhalation.Clinical efficacy,inflammatory factors[serum interleukin-6(IL-6),interleukin-10(IL-10),and tumour necrosis factor-α(TNF-α)],disease regression[Chronic Obstructive Pulmonary Disease Assessment Test(COPD),Assessment Test(CAT)]and adverse effects were compared and analysed between the two groups.Results:The treatment efficiency of the observation group was significantly higher than that of the control group(P<0.05).After treatment,serum IL-6,IL-10,and TNF-α levels were decreased in the two groups,and the observation group was significantly lower than the control group(P<0.05).The CAT scores of patients in the two groups decreased after discharge,and the observation group was significantly lower than the control group(P<0.05);there was no significant difference in the occurrence of adverse reactions between the groups(P>0.05).Conclusion:The clinical efficacy of budesonide nebulised inhalation for the treatment of patients with high eosinophilic AECOPD is remarkable,which can effectively improve the level of inflammatory factors and accelerate the recovery of the patients,with a certain degree of safety.
NETL
NSTL
万方数据
维普
